Skip to main content
HES.
HES

Research

Translational clinical research, cross-cutting hospital practice: from pharmacokinetics to pharmacovigilance, antimicrobials, biologics, parenteral nutrition and health economics.

How we research

Evidence born on the clinical frontline.

We start from real clinical questions across very different areas: what a healthcare professional meets on Monday morning without an answer. We design rigorous studies that answer those questions, in an independent, translational way, with methodological rigor.

  1. 01

    Multicentre studies

    A network of partner hospitals with central coordination, harmonised protocols and transparent data governance.

  2. 02

    Investigator-initiated research

    IIR with academic rigor: hypothesis set by the clinician, pre-specified statistics, independent publication regardless of funding source.

  3. 03

    Real-world evidence (RWE/RWD)

    Electronic health records, therapeutic drug monitoring and patient-reported outcomes (PROMs/PREMs) as complementary sources to the classical trial.

Areas of interest

We work across different clinical fronts.

Relevant questions are not confined to one domain. HES designs and runs research across the areas where daily practice needs better or faster evidence.

  • 01

    Clinical pharmacokinetics

    TDM, precision dosing, narrow therapeutic index drugs.

  • 02

    Biologic therapies

    IBD, rheumatology, dermatology, onco-haematology: response, loss and optimisation.

  • 03

    Antimicrobials

    Stewardship, resistance, dosing in critically ill patients.

  • 04

    Parenteral nutrition

    IV admixtures, compatibility, safety and traceability.

  • 05

    Pharmacovigilance

    Real-world signals, adverse reactions, reporting and continuous learning.

  • 06

    Health economics

    Cost-effectiveness, budget impact, applied economic evaluation.

  • 07

    Patient-reported outcomes

    PROMs and PREMs integrated as primary or secondary endpoints.

  • 08

    Digital innovation

    Clinical software, applied AI, integration into HIS/EHR and algorithmic governance.

Active lines

Some of the studies we have open today.

  1. OPTIBIO-EIIComing soonBiologics · IBD

    Optimising biologic therapy in IBD

    Multicentre study combining pharmacokinetic monitoring with patient-reported outcomes (PROMs/PREMs) collected via NAVETA, across a network of partner hospitals.

  2. KINET-RWEIn validationPharmacokinetics · Applied AI

    Clinical validation of Kinet-IA

    Prospective evaluation of Kinet-IA in hospital settings: model performance, safety, integration in the clinical workflow and clinical acceptability.

Partner network

We work with hospitals, institutes and scientific societies.

We coordinate with hospital pharmacy services, accredited research groups (IRYCIS among others) and scientific societies (SEFH, PkGEN, SEFV, SEFAP). If your hospital or group wants to join a study, get in touch.

  • H.U. Fuenlabrada (SERMAS)
  • H.U. Ramón y Cajal · IRYCIS
  • H.U. de Getafe
  • SEFH · PkGEN network

Proposing a study or adding your centre?

We work with academic rigor and hospital scale. Tell us the clinical question — in any area — and we'll design it with you.

Propose research